New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
January 04, 2023 07:30 ET
|
XOMA Corporation
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
XOMA Declares Quarterly Preferred Stock Dividends
December 22, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
November 22, 2022 07:01 ET
|
XOMA Corporation
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475...
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
November 03, 2022 07:30 ET
|
XOMA Corporation
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five...
XOMA Declares Quarterly Preferred Stock Dividends
September 21, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
August 04, 2022 07:30 ET
|
XOMA Corporation
The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rezolute and Day...
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 20, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events
May 05, 2022 07:30 ET
|
XOMA Corporation
Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has announced its...